-
HIT-CF Project to Explore Potential Therapy ELX-02, Developed by Eloxx
Eloxx Pharmaceuticals has joined the European HIT-CF Project to explore the clinical potential of its lead candidate ELX-02 to treat rare CF mutations. Click here to learn more.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.